NEW YORK, April 26-DiAthegen and TissueInformatics said today that they would be working together to find new drug targets and diagnostics for obesity and type II diabetes.
The research agreement, slated to last five years, seeks to correlate gene expression changes to histological changes during the initiation and progression of type II diabetes. The studies will include both animal and human tissues.
DiAthegen will supply animal modeling, molecular biology and transgenic animal services to the cooperative effort.
TissueInformatics will provide automated tissue imaging, tissue analysis and gene expression capabilities.
The companies did not disclose financial details of the arrangement.
DiAthegen, an Athens, Ohio startup, seeks to develop new diagnostics and therapeutics for obesity, diabetes and hyperinsulinemea through genomic and animal models.